Lobenzarit disodium inhibits the constitutive NO-cGMP metabolic pathways. Possible involvement as an immunomodulatory drug
1995

Lobenzarit Disodium and Its Effects on Inflammation

publication Evidence: moderate

Author Information

Author(s): J. Padrón, A. Rojas, L. Glaria, L. Caveda, R. Delgado, M. Torres, O. Martinez, E. López, A. Beltrán, M. Palacios

Primary Institution: Center of Pharmaceutical Chemistry, Department of Pharmacology and Toxicology, Havana City, Cuba

Hypothesis

Does lobenzarit disodium (CCA) inhibit the production of guanosine 3',5'-cyclic monophosphate (cGMP) and affect nitric oxide generation?

Conclusion

Lobenzarit disodium significantly inhibits the production of cGMP and interferes with nitric oxide generation.

Supporting Evidence

  • CCA inhibits cGMP production almost completely at concentrations of 1 mM.
  • CCA shows a concentration-dependent inhibition of nitric oxide generation.
  • Previous findings suggest CCA enhances the T suppressor/T helper lymphocyte ratio.

Takeaway

Lobenzarit disodium is a new drug that helps reduce inflammation by blocking certain chemicals in the body.

Methodology

The study involved biochemical assays to measure cGMP and citrulline production in rat brain cytosol after treatment with CCA.

Participant Demographics

Male Sprague-Dawley rats weighing 180-200 g were used.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication